

GLAXOSMITHKLINE PLC  
Form 6-K  
October 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc

(the

Company

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, HR
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

|                          |   |  |          |           |          |        |          |        |                          |  |
|--------------------------|---|--|----------|-----------|----------|--------|----------|--------|--------------------------|--|
| a)                       | Description of the financial instrument<br><br>Nature of the transaction<br><br>Price(s) and volume(s)<br><br>Aggregated information<br>d) Aggregated volume<br>Price<br><br>Date of the transaction<br>e) the transaction<br>f) Place of | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882<br><br>Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on shares held in the Deferred Annual Bonus Plan Post-Tax.<br><table border="0" style="margin-left: 20px;"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">£17.0319</td> <td style="text-align: right;">32.163</td> </tr> <tr> <td style="text-align: right;">£17.0319</td> <td style="text-align: right;">32.345</td> </tr> <tr> <td colspan="2" style="text-align: right;">n/a (single transaction)</td> </tr> </table><br>2016-10-13<br>London Stock Exchange (XLON) | Price(s) | Volume(s) | £17.0319 | 32.163 | £17.0319 | 32.345 | n/a (single transaction) |  |
| Price(s)                 | Volume(s)   |  |          |           |          |        |          |        |                          |  |
| £17.0319                 | 32.163  |  |          |           |          |        |          |        |                          |  |
| £17.0319                 | 32.345  |  |          |           |          |        |          |        |                          |  |
| n/a (single transaction) |   |  |          |           |          |        |          |        |                          |  |

the transaction

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: October 17, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc